BCL-2 as therapeutic target for hematological malignancies.

about

Dual targeting of survivin and X-linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC-27 cells

P2860

Q57165703-F3C4ABA4-0854-4AD8-821E-99B002DFDAFA

P2860

BCL-2 as therapeutic target for hematological malignancies.

Item

http://www.wikidata.org/entity/Q53684488

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

BCL-2 as therapeutic target for hematological malignancies.

@en

BCL-2 as therapeutic target for hematological malignancies.

@nl

type

Item

label

BCL-2 as therapeutic target for hematological malignancies.

@en

BCL-2 as therapeutic target for hematological malignancies.

@nl

prefLabel

BCL-2 as therapeutic target for hematological malignancies.

@en

BCL-2 as therapeutic target for hematological malignancies.

@nl

P1476

BCL-2 as therapeutic target for hematological malignancies.

@en

P2093

Glaciano Nogueira Ribeiro

http://www.w3.org/2001/XMLSchema#string

Guilherme Fleury Perini

http://www.w3.org/2001/XMLSchema#string

Jorge Vaz Pinto Neto

http://www.w3.org/2001/XMLSchema#string

Laura Tojeiro Campos

http://www.w3.org/2001/XMLSchema#string

Nelson Hamerschlak

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Hallmarks of Cancer: The Next Generation

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

miR-15 and miR-16 induce apoptosis by targeting BCL2

Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics

Targeting BCL2-Proteins for the Treatment of Solid Tumours

Solution structure of the antiapoptotic protein bcl-2

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Mechanisms of caspase activation and inhibition during apoptosis.

P2888

s13045-018-0608-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13045-018-0608-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103934836

http://www.w3.org/2001/XMLSchema#string

P698

29747654

http://www.w3.org/2001/XMLSchema#string

P921

peptide

neoplasm proteins

P932

5946445

http://www.w3.org/2001/XMLSchema#string

BCL-2 as therapeutic target for hematological malignancies.

about

P2860

P2860

BCL-2 as therapeutic target for hematological malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932